Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Can we cure refractory Hodgkin’s lymphoma with transplantation?

Bone Marrow Transplantation volume 56, pages 278–281 (2021)Cite this article

Subjects

Allogeneic hematopoietic stem cell transplantation (AHSCT) has been traditionally performed for patients with hematological malignancies in remission at transplantation, as relapse rate has been very high.

Hodgkin’s lymphoma (HL) is a disease of adolescents and younger adults. Others and us have reported very good outcomes for patients with HL receiving transplantation. More recently, haploidentical transplantation (HaploSCT) has been shown to be associated with very good results, at least as good as HLA matched donor transplants, and several groups documented lower relapse rate with haploidentical donors as compared with HLA matched donor transplants [1,2,3,4,5]. However, most patients are transplanted after achieving complete remission (CR).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Post-transplant outcomes.

References

  1. Martinez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the lymphoma working party of the European society for blood and marrow transplantation. J Clin Oncol: Off J Am Soc Clin Oncol. 2017;35:3425–32. https://doi.org/10.1200/jco.2017.72.6869.

    Article  CAS  Google Scholar 

  2. Lacerda MP, Arrais Rodrigues C, Pereira AD, Novis Y, Fonseca M, Silva RL, et al. Human leukocyte antigen-haploidentical transplantation for relapsed/refractory Hodgkin lymphoma: a multicenter analysis. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2017;23:705–7. https://doi.org/10.1016/j.bbmt.2017.01.079.

    Article  CAS  Google Scholar 

  3. Gauthier J, Castagna L, Garnier F, Guillaume T, Socie G, Maury S, et al. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone marrow Transplant. 2017;52:689–96. https://doi.org/10.1038/bmt.2016.349.

    Article  CAS  PubMed  Google Scholar 

  4. Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone marrow Transplant. 2017;52:797 https://doi.org/10.1038/bmt.2017.26.

    Article  CAS  PubMed  Google Scholar 

  5. Marani C, Raiola AM, Morbelli S, Dominietto A, Ferrarazzo G, Avenoso D, et al. Haploidentical transplants with post-transplant cyclophosphamide for relapsed or refractory Hodgkin lymphoma: the role of comorbidity index and pretransplant positron emission tomography. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2018;24:2501–8. https://doi.org/10.1016/j.bbmt.2018.07.025.

    Article  CAS  Google Scholar 

  6. Brammer JE, Khouri I, Gaballa S, Anderlini P, Tomuleasa C, Ahmed S, et al. Outcomes of haploidentical stem cell transplantation for lymphoma with melphalan-based conditioning. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2016;22:493–8. https://doi.org/10.1016/j.bbmt.2015.10.015.

    Article  Google Scholar 

  7. Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2013;19:344–56. https://doi.org/10.1016/j.bbmt.2012.08.011.

    Article  CAS  Google Scholar 

  8. Burroughs LM, O’Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2008;14:1279–87. https://doi.org/10.1016/j.bbmt.2008.08.014.

    Article  Google Scholar 

  9. Mariotti J, Devillier R, Bramanti S, Sarina B, Furst S, Granata A, et al. T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with HLA-identical related donors. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2018;24:627–32. https://doi.org/10.1016/j.bbmt.2017.11.030.

    Article  CAS  Google Scholar 

  10. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, et al. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016;122:3316–26. https://doi.org/10.1002/cncr.30180.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, et al. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020;135:449–52.

    Article  Google Scholar 

  12. Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, et al. Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2019;25:1859–68. https://doi.org/10.1016/j.bbmt.2019.05.025.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Stefan O. Ciurea

    Present address: Professor of Clinical Medicine, Division of Hematology/Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, 101 The City Drive South, Building 200, Room 450, ZOT 4061, Orange, CA, 92868, USA

  2. These authors contributed equally: Alina Tanase, Anca Colita

Authors and Affiliations

  1. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Stefan O. Ciurea, Samer Srour, Neeraj Saini, Jin Im, Jeremy Ramdial, Issa Khouri, Paolo Anderlini, Uday Popat, Chitra Hosing & Richard E. Champlin

  2. Center of Excellence in Applied Epidemiology and Hematopoietic Stem Cell Transplant Program, Thammasat University, Pathumthani, Thailand

    Piyanuch Kongtim

  3. Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Hun J. Lee, Luis E. Fayad & Fredrick B. Hagemeister

  4. Bone Marrow Transplant Unit, Fundeni Clinical Institute, Bucharest, Romania

    Ana M. Bica, Lavinia Lipan, Oana Craciun, Cristina G. Jercan, Alina Tanase & Anca Colita

  5. Titu Maiorescu University, Bucharest, Romania

    Alina Tanase

  6. Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

    Anca Colita

Authors
  1. Stefan O. Ciurea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Piyanuch Kongtim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samer Srour
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Neeraj Saini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jin Im
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jeremy Ramdial
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Issa Khouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Paolo Anderlini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Uday Popat
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Chitra Hosing
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Richard E. Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hun J. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Luis E. Fayad
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Fredrick B. Hagemeister
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ana M. Bica
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Lavinia Lipan
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Oana Craciun
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Cristina G. Jercan
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Alina Tanase
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Anca Colita
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SOC contributed with data collection, interpretation of the results and wrote the manuscript; PK Contributed with statistical analysis and interpretation, manuscript writing, reviewed and approved the manuscript. SS, JI, IK, PA, UP, CH, REC, AMB, LL, OC, CGJ contributed with patient care, reviewed and approved the manuscript. AT, AC contributed with data collection and interpretation of results, reviewed and approved the manuscript.

Corresponding author

Correspondence to Stefan O. Ciurea.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ciurea, S.O., Kongtim, P., Srour, S. et al. Can we cure refractory Hodgkin’s lymphoma with transplantation?. Bone Marrow Transplant 56, 278–281 (2021). https://doi.org/10.1038/s41409-020-0989-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-0989-z

Search

Advanced search

Quick links